ServiceNow Inc vs Sana Biotechnology Inc — how do they compare? ServiceNow Inc trades at $101.3 (market cap $107.98B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: ServiceNow Inc is far larger — about 123.6× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| NOW | SANA | |
|---|---|---|
Market Cap | $107.98B | $873.84M |
Sector | Technology | Health |
52-Week High | $199.24 | $5.92 |
52-Week Low | $83.00 | $2.68 |
Enterprise Value | $105.23B | $848.03M |
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $103.24, down 0.74% today, with a bearish technical signal but strong fundamentals including 76.56% gross margins and consistent revenue growth to $13.28B in 2025. The stock shows robust cash flow generation of $5.44B from operations and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth opportunities and conference presentations.
Outlook remains positive with an 85.51% analyst buy rating and $135.14 consensus price target, suggesting 31% upside. Key risks include high valuation multiples (P/E 62.32) and competitive pressures in enterprise software. Earnings execution and AI adoption present the primary catalysts for continued appreciation.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →